Navigation Links
Endologix Reports 47% Third Quarter 2009 Revenue Growth
Date:10/27/2009

2008. Marketing and sales expenses increased to $19.8 million in the first nine months of 2009, up from $18.0 million in the same period last year. Research, development and clinical expenses were $4.5 million in the first nine months of 2009, compared to $4.7 million in the same period last year. General and administrative expenses decreased to $6.3 million in the first nine months of 2009, down from $7.3 million in the same period last year.

Endologix reported a net loss for the third quarter of 2009 of $156,000, or $0.00 per share, compared with a net loss of $3.0 million, or $0.07 per share, for the third quarter of 2008. For the nine months ended September 30, 2009, the Company reported a net loss of $1.8 million, or $0.04 per share, compared with a net loss of $10.4 million, or $0.24 per share, for the nine months ended September 30, 2008.

Total cash and cash equivalents were $21.1 million as of September 30, 2009, compared with total cash and cash equivalents of $7.6 million as of December 31, 2008. In August 2009, the Company raised net proceeds of $14.7 million in an underwritten public offering, and in September, made an unscheduled debt repayment of $4.5 million.

"During the third quarter we continued to improve our balance sheet, generating $2.7 million in positive cash flow from operations and raising net proceeds of $14.7 million in an underwritten public offering. In addition, we have paid off our bank debt, putting the Company in a strong financial position to execute on our growth strategy," stated Endologix Chief Financial Officer Bob Krist.

Financial Guidance

The Company is re-affirming its full year 2009 guidance of revenue in the range of $51 to $53 million.

Conference Call Information

Endologix management will host a conference call to discuss these topics today beginning at 5:00 p.m. Eastern time (2:00 p.m. Pacific time). To participate via teleph
'/>"/>

SOURCE Endologix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Endologix Comments on Alleged Patent Infringement
2. Endologix Responds to Alleged Patent Infringement
3. Endologix to Report Third Quarter 2009 Financial Results on October 27, 2009
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Spherix Reports Second Quarter Earnings
6. Tapestry Reports Second Quarter 2007 Results
7. Callisto Reports on Second-Quarter 2007 Milestones
8. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
9. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
10. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
11. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , May 21, 2013 Reportlinker.com ... is available in its catalogue: ... Reimbursement Scenario for Medical Devices in the ...   Changing Regulatory and ... US Market   ...
(Date:5/21/2013)... Calif. , May 21, 2013 /PRNewswire/ ... ), a specialty pharmaceutical company focused on ... for the treatment of acute and breakthrough ... in a placebo-controlled Phase 3 study of ... analgesia) System (NanoTab System), the primary efficacy ...
(Date:5/21/2013)... N.C. and HENDERSONVILLE, N.C. ... Medicare bidding procurement program for home medical equipment ... North Carolina to lay off employees ... the quality of service and products received by Medicare ... Under the defective and dangerous program, the Centers ...
Breaking Medicine Technology:Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 2Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 3Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 4Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 6Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 7Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 8Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 9Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 10North Carolina Business Owners At Risk Because Of Defective Medicare Bidding Program 2North Carolina Business Owners At Risk Because Of Defective Medicare Bidding Program 3North Carolina Business Owners At Risk Because Of Defective Medicare Bidding Program 4
... Dec. 22 Mylan Inc. (Nasdaq: MYL ) today ... approval from the U.S. Food and Drug Administration (FDA) under ... New Drug Application (NDA) for Efavirenz Tablets, 50 mg, 100 ... form were developed by Matrix for use in treating pediatric ...
... , , , , ... announced that it has entered into an agreement with Laboratoires ... lipase. , DSM has successfully completed process development and commenced ... and Phase I clinical needs. DSM BioSolutions manufactures the lipase ...
Cached Medicine Technology:Mylan Receives Tentative FDA Approval Under PEPFAR for Matrix Laboratories' New Drug Application (NDA) for Efavirenz Tablets 2DSM to Manufacture 'MS1819' Lipase Compound for Mayoly Spindler 2DSM to Manufacture 'MS1819' Lipase Compound for Mayoly Spindler 3DSM to Manufacture 'MS1819' Lipase Compound for Mayoly Spindler 4
(Date:5/21/2013)... The Special Olympics Missouri State Summer Games will bring more ... Columbia. This state-level event takes place May 30-June 2, on ... and at Hickman High School and Town & Country Lanes. ... 7:30 p.m. Friday, May 30 with the Opening Ceremony. The ... of Athletes, the culmination of the statewide Law Enforcement Torch ...
(Date:5/21/2013)... significantly more likely than their normal-weight counterparts to ... disrupts continuity of care and leads to more ... , The practice of "doctor shopping" among overweight ... with the health care system, whether that be ... advice by providers, or improperly sized medical equipment ...
(Date:5/21/2013)... May 21, 2013 Children using ... Sophono, Inc., experience audiological results comparable to the ... many fewer complications, according to a new study. ... that Sophono’s abutment-free technology performs just as well ... with many fewer complications,” says Jim Kasic, president ...
(Date:5/21/2013)... 21 (HealthDay News) -- Urban elementary school children ... sleep problems and suffer academically, new research indicates. ... seven to nine, we found that compromised lung ... impaired academic performance," said study author Daphne ... behavior at Brown University,s Alpert Medical School in ...
(Date:5/21/2013)... Positively charged gold nanoparticles are usually toxic to ... nanoparticle toxicity. Mayo Clinic researchers found out why, ... against ovarian cancer cells. The discovery is detailed ... Journal of Biological Chemistry ., "This study identifies ... by preventing the cell death or apoptosis which ...
Breaking Medicine News(10 mins):Health News:Special Olympics Missouri Athletes Ready to Show Off Skills in Columbia 2Health News:Special Olympics Missouri Athletes Ready to Show Off Skills in Columbia 3Health News:'Doctor shopping' by obese patients negatively affects health 2Health News:'Doctor shopping' by obese patients negatively affects health 3Health News:Abutment-Free Sophono Systems Produce Comparable Study Results to Cochlear’s Baha Products, With Fewer Complications 2Health News:Abutment-Free Sophono Systems Produce Comparable Study Results to Cochlear’s Baha Products, With Fewer Complications 3Health News:Sleepless Nights May Hurt School Performance of Kids With Asthma 2Health News:Mayo Clinic: How gold nanoparticles can help fight ovarian cancer 2
... WM Healthcare Solutions, Inc. (WMHS), a subsidiary ... has purchased substantially all of the assets of ... pharmaceutical waste management consulting services to the U.S. ... other custom consulting services, in addition to the ...
... World Voice Day, April 16, 2009) NEW YORK, April 16 ... musical theater singers in the New York area received a ... cords in April at the second annual free Voice Screening ... Eye and Ear Infirmary and MusiCares, the charitable ...
... run the 2009 Bank of America Chicago Marathon on October 11th with ... is approaching, so please apply by April 20th, 2009 at www.ChristopherReeve.org/TeamReeve ... ... Chicago Chapter of the Christopher & Dana Reeve Foundation announces the ...
... Launches ORBIT, Open-Source Robotic Biorepository & Informatics Technology MILWAUKEE, April 15 , ... Informatics Technology, ... developing ... library of blood samples and privacy-protected ...
... 15 Fundacion Azteca in Mexico and,Fundacion Azteca ... join efforts to,commemorate the 50th Movimiento Azteca. ... conglomerate founded by entrepreneur Ricardo B. Salinas.,Through a ... and,funds to improve the well-being of both mother ...
... always been a brand about lifting spirits and lending their happy ... the brand,s 50th Anniversary celebration, nine celebrity mothers have united for ... Cause . The celebrity designers include: ... Paltrow, Catherine Bell, Elisabeth Hasselbeck and Garcelle Beauvais-Nilon . ...
Cached Medicine News:Health News:Waste Management Subsidiary Acquires PharmEcology(R) Associates, LLC 2Health News:Singers Hit High Notes in Free Voice Screening at The New York Eye and Ear Infirmary 2Health News:Attention Runners: Run the 2009 Bank of America Chicago Marathon with Team Reeve 2Health News:Attention Runners: Run the 2009 Bank of America Chicago Marathon with Team Reeve 3Health News:Fundacion Azteca and Fundacion Azteca America Present 50th Movimiento Azteca to Increase Awareness and Raise Funds for Prenatal and Natal Care 2Health News:Fundacion Azteca and Fundacion Azteca America Present 50th Movimiento Azteca to Increase Awareness and Raise Funds for Prenatal and Natal Care 3Health News:Lilly Pulitzer(R) Launches A Colorful Cause Celebrity Designed Collection for EBMRF 2
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
For use with catalog #0454....
For use with catalog #0454....
Immuno-turbidimetric Assay of D-Dimer by STA© Analyzers. Microlatex particles coated with two different mouse monoclonal anti-human D-Dimer antibodies....
Medicine Products: